RE:RE:RE:RE:Oncolytics Biotech Announces Key Progress & Upcoming StudiesThese following 7 cancers involve the use of pelareorep as a monotherapy or in combination with other cancer agents and should be affecting something "critical" for ONCY in the next couple of months, now that the final results for Bracelet-1 have been finally announced and recently shared with Big Pharma, who awaited its release. (1) HR+/HER2 negative metastatic breast cancer;
(2) Triple Negative Breast Cancer (TNBC);
(3) pancreatic cancer with pelareorep + ICI (atezolizumab) + n-paclitaxel;
(4) pancreatic cancer with pelareorep + ICI (atezolizumab) + folfirinox,
(5) anal (SCCA) cancers,
(6) 3rd line colorectal cancers (CRC) with pelareorep + ICI (atezolizumab),
(7) pelareorep effective as a single dose in the treatment of Hepatocellular carcinoma cancer (HCC).
Now ONCY has said it is scaling-up talks with its partners Roche and Pfizer, as well as European and Asian biotechnology companies like Sanofi, AstraZeneca and Daichii Sanyo, for example, along with MerckKGaA, Novartis, Merck (MSD) US, as well as several other Big Pharma and Big Biotech companies, such as BMS.
ONCY's pelareorep in pancreatic cancer / Goblet 1 Phase 2 timeline:
- June 2023 ONCY's pelareorep is selected for PanCan's Precision Promise Pivotal Phase 3 Platform Trial.
- September 2023 ONCY announces US$5 million PanCan Therapeutics Accelerator Award grant
- October 2023 ONCY presents positive pancreatic cancer data at ESMO 2023
- November 2023 ONCY updates its pancreatic program for pelareorep
- March 2024 ONCY files amendment with European/German Paul Ehrlich Institute (PEI) for pelareorep pancreatic cancer clinical trial approval
- May 2024 ONCY announces GCAR collaboration in the advancement pf pelareorep + atezolizumab + nab-paclitaxel combination in early/first-line PDAC
- May 2024 ONCY receives German regulatory PEI clearance to evaluate pelareorep combination therapy in pancreatic cancer + folfirinox +/- anti-PD-L1 - announces Germany's AIO to run pre-registration enabling folfirinox in early/first-line pancreatic cancer clinical trial
- June 2024 ONCY announces first patient dosing (1st of 15 in Stage 1)) in pelarorep/folfionox AIO run clinical trial. Stage 2 will enroll another 17 early stage pancreatic cancer patients.
ONCY's pelareorep in anal cancer / Goblet-1 Phase 2 timeline:
- November 2023 ONCY / Germany's AIO announce pelareorep/Roche atezolizumab PD-L1 success in Stage 1 anal (SCCA) cancer
- February 2024 ONCY announces Stage 2 enrollment expansion in Germany's AIO run Goblet-1 Phase 2 pelareorep/ Roche atezolizumab PD-L1 anal cancer (SCCA) cohort
ONCY's pelareorep's Bracelet-1 clinical trial in metastatic breast cancer cancer timeline:
https://oncolyticsbiotech.com/investor-overview/news/?_sft_drug_category=bracelet-1